title: [Use of enfurvitide in pregnancy in HIV positive women in seven cases].
abstract: OBJECTIVE
  With a panel of more than 22 drugs, the treatment of HIV subjects is nowadays quite easier. But due to the number of multiparus women often harbouring a multidrug resistant virus, or seen late in pregnancy or inobservant, taking care of these pregnancies remains difficult. The use of enfuvirtide seems quite interesting for these situations.
  
  
  METHODS
  In a retrospective study, we have focused our work on the consequences of enfuvirtide used in seven pregnancies, paying particular attention to efficacy, pharmacokinetics and tolerance.
  
  
  RESULTS
  The use of enfuvirtide during 30 days in average seems safe and the tolerance was satisfactory in all seven cases. All infants are seronegative without abnormalities. The dosages in umbilical cord were negative. Five women experienced an elective caesarean, one had caesarean section in emergency, and one had a vaginal delivery.
  
  
  CONCLUSIONS
  The 23 cases published in the English literature indicate the interest of enfuvirtide use in these difficult situations. Indeed, enfuvirtide is injectable, favouring the adherence; it has a good tolerance, a quick efficacy and no placental transfer. Evidently, enfuvirtide is always prescribed in association.
authors.affiliation: Unité maladies infectieuses, hôpital Jean-Verdier (AP-HP), Seine-Saint-Denis, 93140 Bondy, France. vincent.jeantils@jvr.aphp.fr
authors.forename: V
authors.initials: V
authors.lastname: Jeantils
authors.forename: C
authors.initials: C
authors.lastname: Alloui
authors.forename: A
authors.initials: A
authors.lastname: Rodrigues
authors.forename: M
authors.initials: M
authors.lastname: Bentata
authors.forename: G
authors.initials: G
authors.lastname: Peytavin
authors.forename: L
authors.initials: L
authors.lastname: Carbillon
mesh_terms: D000328:Adult; D002585:Cesarean Section; D036861:Delivery, Obstetric; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D006679:HIV Seropositivity / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D010446:Peptide Fragments / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide